SG/PUT/NOVO-NORDISK B/600/0.1/20.06.25 Stock

DE000SU9CVW0

Market Closed - Boerse Frankfurt Warrants 15:38:07 2024-07-05 EDT
0.22 ^EUR	-4.35%

Current month	+4.76%
1 month	-8.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/PUT/NOVO-NORDISK B/600/0.1/20.06.25

Latest news about NOVO NORDISK A/S

Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	07-05	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	07-05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	07-05	MT
Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector	07-05	RE

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.22	-4.35%
24-07-04	0.23	0.00%
24-07-03	0.23	+9.52%
24-07-02	0.21	+10.53%
24-07-01	0.19	-9.52%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 03:38 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SU9CVW
ISIN	DE000SU9CVW0
Date issued	2024-02-14
Strike	600 kr
Maturity	2025-06-20 (350 Days)
Parity	10 : 1
Emission price	0.58 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.65 €
Lowest since issue	0.18 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	55.51x
Moneyness	0.6160
Difference Strike	-374 kr
Difference Strike %	-62.33%
Spread	0.01 €
Spread %	4.17%
Intrinsic value	0.000000
Present value	0.2350

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company